큐리언트

115180KOSDAQ

58.4 / 100

Reference Date: 2026-09-08

Financial Score14.0 / 40

News Sentiment19.4 / 25

Momentum13.0 / 20

Disclosure12.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Rose 12.4% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Curient is a biotech company specializing in new drug development, established with government and international investments to advance Korea's pharmaceutical and biotech industry. Collaborating with institutions like the French Pasteur Institute and Germany's Max Planck Society, it focuses on infectious disease and oncology/immunology therapies. Partnering with MSD, it develops combination therapies with Keytruda, and reported consolidated sales of 92 billion KRW in 2024.

Number of Employees

32people

Average Salary

141.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

—Industry Average 1.203.5Point

ROE

-68.05Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

48.23Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼11.2% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼13.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -57.4% (declining, 3yr)

Detailed News Sentiment

6 totalPositive 5Neutral 1Negative 0Average Sentiment Score 77.5

Neutral
외부투자 타진했던 큐리언트, 결국 1016억 주주배정 증자
큐리언트가 외부 투자자 유치 실패 후 주주배정 증자를 통해 자금을 조달하기로 결정했으나, 시장 상황에 따른 제약으로 인해 직접적인 긍정 또는 부정 영향은 제한적이다.
Positive
큐리언트, 1016억 주주배정 유상증자?"이중 페이로드 ADC에 투자"
큐리언트의 주주배정 유상증자 결정으로 자금 조달 성공, 이중 페이로드 ADC 분야 투자 확대로 긍정적 전망.
Positive
남기연 큐리언트 대표 "하반기 이벤트 자신감에 주주배정 유증 선택"
큐리언트는 하반기 이벤트를 통한 기업 가치 상승 기대에 따라 주주배정 유상증자를 결정, 긍정적인 미래 전망을 반영.

Detailed Momentum

52-week position3.0Point

52w lower range (35%)

Current 25,750Won52-week high 50,90052-week low 11,660

1-month return5.0Point

1m +12.45% (rising)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

6 totalPositive 1Neutral 5Negative 0

Neutral기업설명회(IR)개최2026-09-07
Positive주요사항보고서(유상증자결정)2026-09-04
Neutral증권신고서(지분증권)2026-09-04
Neutral기업설명회(IR)개최2026-09-04
Neutral[기재정정]투자판단관련주요경영사항(임상시험계획승인신청등결정) (만성 이식편대숙주질환 환자 대상 Q702 단독치료요법의 스페인 임상 제1b상 임상시험계획 승인)2026-08-18